24/7 Market News Snapshot 10 March, 2025 – SciSparc Ltd. Ordinary Shares (NASDAQ:SPRC)

March 10, 2025

DENVER, Colo., 10 March, 2025 (247marketnews.com) – (NASDAQ:SPRC) are discussed in this article.
In the pre-market trading session, SciSparc Ltd. (NASDAQ:SPRC) has captured significant investor attention, exhibiting a remarkable jump to $0.476, reflecting a notable 48.94% increase from the prior close of $0.320. This surge is bolstered by a substantial trading volume of 11.04 million shares, suggesting heightened investor confidence and potentially indicating a breakout opportunity in the market for the biotech firm. With such momentum, SciSparc is positioned as a key player in the sector, warranting close observation from traders and investors alike.

In addition to its market activity, SciSparc has announced a pivotal advance in its collaboration with Clearmind Medicine Inc. (NASDAQ:CMND). The South Korean Intellectual Property Office (KIPO) has officially published a significant patent application focused on an innovative combination treatment that utilizes Clearmind’s 5-methoxy-2-aminoindane (MEAI) alongside SciSparc’s Palmitoylethanolamide (PEA) aimed at addressing cocaine addiction. This milestone emerges from encouraging preclinical trial results conducted by Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center. Key findings demonstrated that subject animals exhibited a marked reduction in cocaine cravings following MEAI treatment.

Further investigations suggested that while MEAI effectively diminished cocaine-seeking behavior, it did not adversely affect responses to natural rewards, highlighting the compound’s specificity in targeting drug-related urges without impinging on the broader reward system. This patent filing complements a growing portfolio aimed at fostering innovative addiction treatment solutions, reinforcing the strategic commitment of both SciSparc and Clearmind to pioneer advancements in mental health therapeutics.

With ongoing programs aimed at various conditions such as epilepsy, Alzheimer’s, chronic pain, and autism, SciSparc is dedicated to leveraging cannabinoids for therapeutic gain, while Clearmind remains focused on developing psychedelic-based treatments for severe mental health challenges. Together, they are poised to significantly influence the landscape of addiction and mental health therapies.

Related news for (SPRC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.